CNS specialist Sage Therapeutics (Nasdaq: SAGE) could have its first commercial product by Christmas.
On Wednesday, the US Food and Drug Administration (FDA) accepted the filing of a New Drug Application (NDA) for the US biotech’s lead product candidate, an intravenous (IV) formulation of brexanolone (SAGE-547), for postpartum depression (PPD).
The FDA has also granted the NDA priority review status and assigned a Prescription Drug User Fee Act target date of December 19 this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze